Applied DNA Schedules Fiscal 2020 Fourth Quarter Financial Results Conference Call for Thursday, December 17, 2020 at 4:30 PM...
09 December 2020 - 1:00AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
"Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing, announced today that it will release financial
results for its fiscal 2020 fourth quarter ended September 30, 2020
after market close on Thursday, December 17, 2020. In conjunction
with the release, the Company has scheduled a conference call at
4:30 p.m. Eastern Standard Time that will also be broadcast live
over the Internet.
What: Applied DNA’s Fiscal 2020 Fourth Quarter Financial
Results Conference Call
When: Thursday, December 17, 2020, at 4:30 p.m. Eastern
Standard Time
Where: Via phone by dialing +1-844-887-9402 (U.S toll
free) or +1-412-317-6798 (international dialers) or via live
webcast.
A telephonic replay of the conference call will be available for
one week and may be accessed by calling +1-877-344-7529 (U.S. toll)
or +1-412-317-0088 (international dialers) with the passcode
10149831. An archive of the webcast will be available for a period
of one year on the ‘IR Calendar’ page of the Investor Relations
section of the Company’s website starting within two hours from the
conclusion of the live call.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping, and pre-clinical nucleic acid-based
therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to, its history of
net losses, limited financial resources, limited market acceptance,
the uncertainties inherent in research and development, our ability
to successfully enter into commercial contracts for the
implementation of our CertainT® platform, disruptions in the supply
of raw materials and supplies, and various other factors detailed
from time to time in Applied DNA’s SEC reports and filings,
including our Annual Report on Form 10-K filed on December 12, 2019
and our subsequent quarterly reports on Form 10-Q filed on February
6, 2020, May 14, 2020 and August 6, 2020, and other reports we file
with the SEC, which are available at www.sec.gov. Applied DNA
undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201208005290/en/
Investor contact: Sanjay M. Hurry, Applied DNA Sciences,
917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2024 to May 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From May 2023 to May 2024